Results 91 to 100 of about 60,436 (245)
Performing Large‐Scale Genetic Analysis in the Bleeding Disorders Community
Haemophilia, EarlyView.ABSTRACT Inherited bleeding disorders encompass a diverse group of conditions caused by genetic defects affecting coagulation factors, fibrinogen, von Willebrand factor, or platelet function. Despite major advances in quantitative and functional laboratory assays, a substantial diagnostic gap remains, particularly in patients with mild or atypical ...
Anna R. Blankstein +6 more
wiley +1 more source
Ticagrelor after Fibrinolytic: Is it Time to Consider? [PDF]
, 2019 Worldwide, ischemic heart disease is the most common cause of death and its frequency is increasing. ST-segment elevation myocardial infarction or STEMIis as form of ischemic heart disease with the highest mortality rate.
Lukito, - +4 more
core +1 more source
Haemophilia, EarlyView.ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini +4 more
wiley +1 more source
The XX Factor in Hemophilia: Diagnostic, Therapeutic, and Research Gaps for Women and Girls
Haemophilia, EarlyView.ABSTRACT Introduction Hemophilia has traditionally been viewed as an X‐linked disorder affecting men and boys, with women and girls labeled as “carriers”, presumed to be clinically unaffected. This paradigm has contributed to under‐recognition, delayed diagnosis, and undertreatment of females with hemophilia‐associated genotypes despite an increasingly
Kelsey Uminski, Ellen Cusano
wiley +1 more source
Effect of tumor necrosis factor on the human fibrinolytic system.
, 1990 We report the effects on the fibrinolytic system of intravenous (IV) recombinant tumor necrosis factor-alpha (rTNF-alpha) infusions in patients with advanced cancers.
N A Berger +4 more
core +1 more source
The Physiology of the Fibrinolytic System.
The Japanese Journal of Physiology, 1993 There are many publications on the biochemical aspects of fibrinolysis and therapeutic effects of thrombolytic drugs in occlusive vessel diseases such as myocardial infarction, cerebrovascular thrombosis and venous thrombosis predisposing to pulmonary embolism.
TAKADA, Akikazu, TAKADA, Yumiko
openaire +3 more sources
Haemophilia, EarlyView.ABSTRACT Introduction Individuals diagnosed with types 1/1C/2A/2M von Willebrand disease (VWD) typically undergo a desmopressin (DDAVP) challenge to assess therapeutic benefit. This involves measuring von Willebrand factor antigen (VWF:Ag), activity (VWF:Act; VWF:RCo/VWF:GPIbM/VWF:Ab), and coagulant factor VIII (FVIII:C) levels 0 (pre), 1, and 4‐h post‐
Michael Shu +7 more
wiley +1 more source
Atrophic Papulosis: A Systematic Review of Pediatric Cases
Pediatric Dermatology, EarlyView.ABSTRACT Background Atrophic papulosis is a rare occlusive vasculopathy that can present with isolated cutaneous disease or with systemic involvement. Pediatric cases are uncommon, and existing reports are heterogeneous, limiting understanding of disease patterns, timing of organ involvement, and outcomes.
Ou Jia Emilie Wang +4 more
wiley +1 more source
Timi Flow Between Streptokinase and Alteplase in Successful Fibrinolytic [PDF]
, 2019 STEMI with onset≤12 hours, necessary to take Primary Percutaneous Coronary Intervention (pPCI), but if there is no facility, another therapy is fibrinolytic, to improve blood flow in the coronary artery and myocardial function, thus reducing infarction
Muhtar, Zulfikri +4 more
core
, 2017 Background: ST elevation myocardial infarction (STEMI) is the most common acute coronary syndrome in adults, and requiring immediate reperfusion. Primary percutaneous coronary intervention (PCI) is the main reperfusion therapy, but because of many ...
Hariawan, Hariadi +2 more
core +1 more source